Pentraxin-3 is a novel biomarker of lung carcinoma

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2395-2399

  Diamandis, Eleftherios P ^a,b,f   Goodglick, Lee ^d   Planque, Chris ^c   Thornquist, Mark D ^e  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

^f MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN 11; PENTRAXIN 3; PROGRANULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; TISSUE TYPES;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; RISK FACTORS; ROC CURVE; SERINE ENDOPEPTIDASES; SERUM AMYLOID P-COMPONENT; SMOKING;

EID: 79954587370     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3024     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics 2009. CA Cancer J Clin 2009;59:225-49.
2. Schiller JH. Current standards of care in small-cell and non-small-cell lung cancer. Oncology 2001;61:3-13.
3. Brambilla E. Classification of broncho-pulmonary cancers (WHO 1999). Rev Mal Respir 2002;19:455-66. (Pubitemid 35332226)
4. Etzioni R, Urban N, Ramsey S, McIntosh M, Schwartz S, Reid B, et al. The case for early detection. Nat Rev Cancer 2003;3:243-52. (Pubitemid 37328860)
5. Molina R, Auge JM, Escudero JM, Marrades R, Viñolas N, Carcereny E, et al. Mucins CA125, CA19.9, CA15.3 and TAG-72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumour Biol 2008;29:371-80.
6. Planque C, Kulasingam V, Smith CR, Reckamp K, Goodglick L, Diamandis EP. Identification of five candidate lung cancer biomarkers by proteomics analysis of conditioned media of four lung cancer cell lines. Mol Cell Proteomics 2009;8:2746-58.
7. Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol 2008;5:588-99.
8. Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010;10:371-8.
9. Planque C, Li L, Zheng Y, Soosaipillai A, Reckamp K, Chia D, et al. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma. Clin Cancer Res 2008;14:1355-62. (Pubitemid 351413915)
10. Diamandis EP, Borgono CA, Scorilas A, Harbeck N, Dorn J, Schmitt M. Human kallikrien 11: an indicatior of favorable prognosis in ovarian cancer patients. Clin Biochem 2004;37:823-9. (Pubitemid 39141126)
11. Pepe MS, Longton G, Janes H. Estimation and comparison of receiver operating characteristic curves. Stata J 2009;9:1-16.
12. Janes H, Longton G, Pepe MS. Accommodating covariates in receiver operating characteristic analysis. Stata J 2009;9:17-39.
13. Diamandis EP, Hoffman B, Sturgeon CM. National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines for the use of tumor markers. Clin Chem 2008;54:1935-39.
14. Kulasingam V, Diamandis EP. Tissue culture-based breast cancer biomarker discovery platform. Int J Cancer 2008;123:2007-12.
15. Qui J, Hanash S. Autoantibody profiling for cancer detection. Clin Lab Med 2009;29:31-46.
16. Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, et al. Occurrence of autoantibodies of annexin 1, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008;26:5060-66.
17. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.
18. Lehtiö J, De Petris L. Lung cancer proteomics, clinical and technological considerations. J Proteomics 2010;73:1851-63.
19. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, et al. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010;16:3452-62.
20. Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R, et al. Differential serum level of specific haptoglobin isoforms in small cell lung cancer. Curr Proteomics 2010;7:49-65.
21. Sardana G, Jung K, Stepham C, Diamandis EP. Proteomic analysis of conditioned media from PC3, LNCaP and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. J Proteome Res 2008;7:3329-38.
22. Biagi E, Col M, Migliavacca M, Dell'Oro M, Silvestri D, Montanelli A, et al. PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno compromised pediatric patients. J Pediatr Hematol Oncol 2008;30:881-5.
23. Willeke F, Assad A, Findeisen P, Schromm E, Grobholz R, von Gerstenbergk B, et al. Overexpression of a member of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer 2005;42:2639-46. (Pubitemid 44442954)
24. Okutani D. The role of long pentraxin 3, a new inflammatory mediator in inflammatory responses. Nihon Rinsho Meneki Gakkai Kaishi 2006;29:107-13.
25. Abderrahim-Ferkoune A, Bezy O, Chiellini C, Maffei M, Grimaldi P, Bonino F, et al. Characterization of the long pentraxin PTX3 as a TBFalpha-induced secreted protein of adipose cells. J Lipid Res 2003;44:994-1000. (Pubitemid 37279659)